Studi sperim entali

Smoking, physical activity and respiratory irregularities in patients with panic disorder

Fumo, attività fisica e irregolarità respiratorie in pazienti affetti da disturbo di panico

EMMA FADD A 1,2,3, ELISA GALIMB ERTI 1,2,3, STEFAN IA CAMMINO 1,2, LAUR A BELLODI 1,2

E-mail: emmafadda@yahoo.it

1Department of Clinical Neuroscience, San Raffaele Scientific Institute of Milan
2School of Psychology, Vita-Salute San Raffaele University of Milan
3Institute of Experimental Neurology (INSP E), Vita-Salute San Raffaele University of Milan

SUMMARY. Background. In the past decades different evidences suggested a relationship between panic disorder (PD) and respiration, among which the presence of different respiratory irregularities at rest in PD patients. It has been hypothesized that PD could be characterized by a dysfunction of those areas involved in the central control of respiration. The aim of the present study was to elucidate possible differences in breath-by-breath respiratory function at rest between a sample of PD patients with agoraphobia and healthy controls (HC), with particular attention to smoking and physical activity as possible relevant factors in the understanding of respiratory dynamics in PD. Methods. Respiratory physiology was assessed in 32 PD patients and 24 HC. Respiratory rate (RR), tidal volume (VT), minute ventilation (VE), and end-tidal CO2 (pCO2) have been assessed. Results. A significant diagnosis-by-smoking interaction was found for mean RR and VT. Mean pCO2 was significantly higher in active than in sedentary patients. Anxiety state did not account for the results. Conclusions. Our findings suggest an abnormal regulation of the respiratory system as a key mechanism in PD. In future studies it should be useful to stratify data taking into account level and intensity of physical activity and smoking behaviour, as well as to consider the cardiac profile and the effect of those variables able to modulate the homeostatic brain functioning.

KEY WORDS: panic disorder, respiration, irregularity, homeostatic brain, smoking, physical activity.
suggested a prominent role of respiratory control mechanisms in the genesis of abnormal anxiety (3).

Starting from clinical evidences for the common appearance of respiratory symptoms during panic attacks, in the last decades some authors postulated the role of respiratory system in the pathophysiology of PD, and different clinical and experimental lines of evidence were proposed as distinguishing markers of that relationship (4). These evidences concern the presence of prominent respiratory symptoms during panic attacks and the intercritical periods, a childhood history of respiratory diseases in up to 40% of PD patients, the relationship between PD and hyperventilation and hyperactivity to inhalation of hypercapnic substances. The sensitivity of PD patients to respiratory tests and the presence of prominent respiratory symptoms during panic attacks seem also to discriminate between a respiratory and a non-respiratory subtype (5-8). Respiratory subtype patients show lower end-tidal CO₂ (pCO₂) basal levels (9,10), a more chronic symptomatology, more serious and frequent nocturnal panic attacks and are more often smokers (11). Moreover, some authors suggested a higher pharmacological responsiveness of respiratory subtype patients compared to the non-respiratory subtype group (12,13).

Another line of evidence that favours a link between PD and respiration refers to the presence of multiple respiratory irregularities at rest in several respiratory parameters, such as respiratory rate (RR), pCO₂, tidal volume (VT) and minute ventilation (VE).

Investigations on resting pCO₂ levels in PD compared to healthy controls (HC) have yielded contradictory results. Some authors observed similar pCO₂ levels in PD patients compared to HC (14-16), even if other studies showed evidences for lower pCO₂ in PD patients (14,17,18). Several studies found similar RR values in PD patients compared to HC (18-20). Few studies reporting a group difference showed several limitations concerning methodological issues and sample selection criteria. Findings from studies investigating VT and VE at rest seem to be the most inconsistent, with increased values in PD patients compared to HC (14,17,21) or no differences between the two groups (18,19,22,23). It has been supposed that inconsistencies could be due to unbalanced samples with regard to gender distribution (22,24), likely to introduce a bias in respiratory outcomes. Great irregularity in breathing pattern of PD patients has been attributed also to frequent sighs (14,25-27).

Finally, some studies have reported greater instability and higher levels of respiratory irregularity and complexity in PD subjects compared with HC in RR, VT, VE and pCO₂, assessed using non-linear measures, such as approximate entropy (14,19,28,29). Results were in line with the traditional measures of those respiratory parameters (i.e. mean ± standard deviation, SD).

Taken together these findings led to the idea that dysfunctions in respiratory control mechanisms may underlie the occurrence of panic attacks (7,30). It has been proposed that respiratory variability might be a candidate as a biological marker of PD, and abnormal breathing patterns, as those observed in PD compared to controls, might indicate instability of the respiratory homeostasis (29).

However, despite the huge literature available, the nature of respiratory abnormalities remains unclear, and studies have not yielded unequivocal results, mostly those assessing respiratory patterns accordingly to their mean and SD values. Inconsistencies could be probably due to methodological issues, like sample size, patients’ medication status and heterogeneity on experimental procedures. Moreover, most studies used mixed samples with and without agoraphobia, not always controlling for possible effects of this variable. Despite the fact that epidemiological and clinical studies focusing on anxiety disorders showed a strong association between smoking and PD (31-36), possible effects of this variable on respiratory function have not been always taken into account. Finally, the relationship between PD and physical activity has not been deepened yet. Early studies focused attention on the relationship between anxiety, agoraphobia and levels of physical activity avoidance. Clark et al. (37) investigated physical activity in patients with PD, and reported that mean hours of daily activity were higher in patients without phobic avoidance than in controls. This result is consistent with recent results from Sakamoto et al. (38). Moreover, some studies showed that physical activity is able to provoke panic attacks in PD patients (39,40), and Bromberg-Fulks and Storey (41) proposed that anaerobic activity could reduce anxiety sensibility in PD patients. Recently, Pfaltz et al. (42) have hypothesized that respiratory irregularities could be observed in PD patients during higher levels of physical activity. They found stronger increases in VT variability during minimal and slow walking in PD patients compared to HC, and atypical respiratory activity was generally not seen in PD during more active states. Despite the increased interest on this issue, it remains unclear whether and how physical activity could be associated with stable baseline respiratory irregularities in PD patients compared to controls.

The aim of the present study was to elucidate possible differences in breath-by-breath respiratory function at rest between a sample of PD patients with ago-

---

Radda E et al.  
Riv Psichiatri 2013; 48(4): 293-300  
294
raphobia and HC, with particular attention to smoking and physical activity as possible relevant factors in the understanding of the respiratory dynamics in PD. Therefore, in this study we investigated 1) the possible effect of smoking on baseline respiratory pattern, and 2) the possible link between physical activity and stable baseline respiratory alterations.

Evaluation of respiratory dynamics included assessment of RR, VT, VE and pCO₂. We decided to assess respiratory parameters by traditional measures, i.e. mean and SD, because these indexes are the most studied in the literature, and for which there is no general consensus concerning the possible presence of irregularities in PD.

**METHODS**

**Participants**

Thirty-two outpatients with PD with agoraphobia (20 women and 12 men) and 24 HC (12 women and 12 men) were recruited from those consecutively referred to the Anxiety Disorders Clinical and Research Unit of the San Raffaele Rurso Hospital (Milan), over a period of 8 months. HC subjects were recruited from the general population by advertisements placed in the nearby of the Vita-Salute University.

DSM-IV-TR diagnoses were obtained by a senior psychiatrist who assessed patients with the Mini-International Neuropsychiatric Interview (M.I.N.I) for DSM-IV Psychiatric Disorders (43). HC had to be free of any current or lifetime psychiatric disorders, and never experienced panic attacks, even paucisymptomatic. The presence of concurrent psychiatric disorders was an exclusion criterion for PD patients.

According to a direct physical examination and a careful collection of medical history, the exclusion criteria for all subjects were 1) severe organic disease, particularly cardiorespiratory, osteomuscular, vestibular and neurologic diseases; 2) significant hypertension (systolic blood pressure >180 mmHg, diastolic pressure >100 mmHg); 3) evidence for mental retardation; 4) pregnancy or epilepsy. Moreover, HC had to be free of any psychotropic drugs, whereas PD patients had to be free of psychotrophic drugs or on stable doses for at least 6 months.

None of the patients had taken fluoxetine in the 6 months before testing. Because many substances can affect respiratory patterns (44), subjects were asked to refrain from alcohol for at least 36 hours, from beverages or food-containing xanthines for at least 8 hours, from nonsteroidal anti-inflammatory drugs for at least 36 hours, and from any eating or smoking for at least 2 hours before assessment of respiratory physiology. All participants gave their written informed consent to the study after a detailed explanation of the entire procedure. The study procedure was approved by the Ethics Committee of Milan ASL.

**Assessment of smoking and physical activity**

In this study, we included non-smokers (i.e., subjects who declared they had never used cigarettes or other tobacco products in their lifetime) and smokers (i.e., subjects with an active tobacco use on a daily basis and with a regular smoking habit). Regular smokers were defined as subjects who smoked on a daily basis for a period of at least 4 weeks continually (34,36,45) and did not quit smoking for a period longer than 6 continuous months in their lifetime. Regular smokers were also classified as nondependent smokers if they had never met DSM-IV criteria for nicotine dependence and as dependent smokers if they had. In our sample, all smokers smoked cigarettes.

Physical activity was also assessed. All subjects were categorized as sedentary if they did not regularly perform sports activity and active if they performed sports, such as volley, running, jogging, fast walking, cycling, swimming, soccer, tennis, and so on, at least once a week during the previous 2 months (46).

**Assessment of respiratory physiology (apparatus)**

We used the Quark b2 stationary testing system (Cosmed, Rome, Italy) to assess respiratory physiology by monitoring respiratory function and pulmonary gas exchange on a breath-by-breath basis, in accordance with the recommendations of the American Thoracic Society and the European Respiratory Society (47,48). The apparatus and procedure have been described elsewhere (28). Briefly, the Quark b2 system consists of a mobile unit containing the principal components, which are connected online to a computer to allow continuous breath-by-breath recording of respiratory parameters. An open, light face mask connects the subject to the respiratory testing system. Before each test, the turbine and the analyzers were calibrated in order to maintain optimal technical characteristics of the apparatus.

**Procedure**

A standardized procedure was used during the entire assessment period to minimize any confounding influences (44). The recording was carried out in a quiet room and took 18 minutes. All subjects were tested between 4:00 p.m. and 6:00 p.m. to avoid biases related to circadian rhythms of respiratory control (49,50). Before the recording started, all subjects rested for 20 minutes and were familiarized with the study apparatus. All subjects were told that the system would assess baseline respiratory physiology and record the respiratory measures during natural breathing at rest. They were instructed to remain seated silently, quietly, and with eyes open during the entire session. They were also told they could stop the session whenever they wanted with a hand signal to the examiner. Before the
recording start, baseline anxiety was assessed with the State (STAI-1) and Trait (STAI-2) Anxiety Inventory (51). A visual analogue scale (VAS) for anxiety, which assesses the degree of global subjective anxiety on a continuum from 0 (no anxiety) to 100 (the worst anxiety imaginable), was administered immediately before (VAS-pre) and after (VAS-post) the recording session. During the whole procedure, the examiner monitored on a computer screen the continuous recording of the respiratory parameters breath-by-breath and interacted with the subjects only before and at the end of the evaluation, to administer the psychometric scales. Any disturbances that could modify the respiratory pattern, such as coughs, sneezes, or laughs, were noted by the examiner directly in the data file during the continuous recording, without interrupting the test.

**Statistical analysis**

Parametric statistical analyses were employed. Continuous data were analyzed by Student’s *t*-test, analysis of variance (ANOVA), analysis of covariance (ANCOVA), and multivariate analysis of covariance (MANCOVA). Nominal data were compared by chi-square ($X^2$) analysis. Statistical analyses were carried out using STATISTICA 6.0 Software.

**RESULTS**

**Epidemiological and clinical variables**

No significant differences in sex distribution ($X^2$=0.875; df=1; *p*>0.05) and age ($t$=-1.62; df=54; *p*>0.05) were observed between HC and PD patients. Educational background was statistically different between the two groups ($t$=4.61; df=54; *p*<0.0001), with higher values in HC. Furthermore, the two groups did not differ on body mass index ($t$=0.44; df=54; *p*>0.05) (Table 1).

The number of subjects who regularly practiced sports was significantly higher in HC than in PD patients ($X^2$=5.03; df=1; *p*<0.05), whereas no significant differences were found between groups in smoker distribution ($X^2$=0.282; df=1; *p*>0.05) (Table 1).

**Self-reported anxiety**

PD patients had significantly higher baseline anxiety levels, as measured by the STAI-1, before assessment of respiratory physiology than HC subjects (38.78 ± 9.71 vs 27.78 ± 5.20) ($t$=-5.529; df=53; *p*<0.00001). Values of STAI-2 were significantly higher in PD patients than in HC (50.14 ± 12.87 vs 36.26 ± 6.57) ($t$=-5.648; df=54; *p*<0.0001). Values on VAS-pre in PD patients were significantly higher than in HC (26.34 ± 24.81 vs 7.33 ± 7.14) ($t$=-3.633; df=54; *p*<0.001). Moreover, values on VAS-post in PD patients were significantly higher than in HC (18.21 ± 20.68 vs 3.08 ± 4.88) ($t$=-3.504; df=54; *p*<0.001) (Table 1). ANOVA for repeated measures showed significant effects of diagnosis (F=16.59, df=1, *p*<0.0001) and time (F=7.03, df=1, *p*<0.01) in the VAS scores, while no significant time-by-diagnosis interaction was found (*p*>0.05).

**Respiratory variables**

A MANCOVA with the STAI-1 score as covariate showed no significant differences in the mean and SD values of any of the respiratory parameters between PD patients and HC. RR means and SDs were 14.57 ± 3.15 and 16.11 ± 3.84 breaths/minute, respectively; VT means and SDs were 0.54 ± 0.24 and 0.55 ± 0.27 liter; VE means and SDs were 7.43 ± 2.50 and 8.55 ± 5.00 l/min; pCO$_2$ means and SDs were 33.93 ± 6.54 and 35.60 ± 6.54 mmHg (5).

An ANCOVA with the STAI-1 score as covariate and medication as grouping factor was performed in the PD group. No differences were found between medicated and unmedicated patients in RR (mean: F=0.17; df=1; *p*=0.67 and SD: F=0.17; df=1; *p*=0.67), VE (mean: F=0.63; df=1; *p*=0.43 and SD: F=0.28; df=1; *p*=0.59) and pCO$_2$ (mean: F=0.77; df=1; *p*=0.38 and SD: F=0.13; df=1; *p*=0.71).

Covariate was significant for VT and VE means and for VT, VE and pCO$_2$ SDs (*p*<0.05) (Table 2).

**Smoking and physical activity**

A MANCOVA with the STAI-1 as covariate and diagnosis and smoking as grouping factors showed no significant diagnosis and smoking effects on all respiratory parameters. A significant diagnosis-by-smoking interaction was found for the mean values of RR (F=4.28; df=1; *p*<0.05) and for the mean values of VT (F=5.31; df=1; *p*<0.05). Covariate was significant for VT and VE means and for VT, VE and pCO$_2$ SDs (*p*<0.05) (Table 3).

**Table 1**

**Table 2**

**Table 3**
Since the X² analysis showed a statistical difference between groups concerning the distribution of sedentary and active subjects, physical activity effect on respiration was analyzed separately in the two groups. An ANCOVA with the STA I-1 score as covariate and sport as grouping factor was performed. In HC, no significant differences in mean and SD values for all respiratory parameters were observed between sedentary and active subjects (all >0.05), except for the pCO₂ mean value that was significantly higher in active patients than in sedentary subjects (F=1.81; df=1; p< 0.05). Covariate was significant for VT, VE and pCO₂ SDs (p< 0.05).

**DISCUSSION**

The aim of the present study was to elucidate possible differences in breath-by-breath respiratory function at rest between a sample of PD patients with agoraphobia and HC, with particular attention to smoking and physical activity as possible relevant factors in the understanding of respiratory dynamics in PD.

Baseline anxiety assessed by the STA I and VAS scales was significantly higher in PD patients than in HC, and this finding is in line with data from the literature (52,53) that show higher trait-state anxiety levels in PD patients than in HC. Moreover, VAS scores for anxiety during the procedure decreased similarly in the two groups, indicating that the procedure was not more anxiogenic for patients than for comparison subjects.

We did not find significant differences between groups in mean and SD for all physiological indexes. Anxiety levels did not account for this result, since we used STA I-1 values as covariate in our analysis. Our findings are in line with part of the available literature. Among those studies that showed similar pCO₂ levels between groups, there are some showing how antipanic medications can modulate respiratory physiology.

### Table 1. Demographic, epidemiological and clinical characteristics of patients with panic disorder (PD) and healthy controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>PD patients (n=32)</th>
<th>Healthy controls (n=24)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>12/20</td>
<td>12/12</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>38.40 ± 12.59</td>
<td>32.54 ± 14.31</td>
<td></td>
</tr>
<tr>
<td>Educational background (years)</td>
<td>13.37 ± 3.78</td>
<td>17.29 ± 1.96</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>23.21 ± 3.91</td>
<td>21.73 ± 3.29</td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>12</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Psychotropic medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free</td>
<td>14</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Stable dose (6 months)</td>
<td>18</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Physical activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>6</td>
<td>12</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Sedentary</td>
<td>23</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>STA I-1</td>
<td>38.78 ± 9.71</td>
<td>27.78 ± 5.20</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>STA I-2</td>
<td>50.14 ± 12.87</td>
<td>36.26 ± 6.57</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>VAS-pre</td>
<td>26.34 ± 24.81</td>
<td>7.33 ± 7.14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VAS-post</td>
<td>18.21 ± 20.68</td>
<td>3.08 ± 4.88</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

STA I-1 and -2: State and Trait Anxiety Inventory; VAS: visual analogue scale.

### Table 2. Respiratory parameters in patients with panic disorder (PD) and in healthy controls

<table>
<thead>
<tr>
<th>Respiratory parameter</th>
<th>PD patients (n=32)</th>
<th>Healthy controls (n=24)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory rate</td>
<td>16.11 ± 3.84</td>
<td>14.57 ± 3.15</td>
<td></td>
</tr>
<tr>
<td>Tidal volume</td>
<td>0.55 ± 0.27</td>
<td>0.54 ± 0.24</td>
<td></td>
</tr>
<tr>
<td>Minute ventilation</td>
<td>8.55 ± 5.00</td>
<td>7.43 ± 2.50</td>
<td></td>
</tr>
<tr>
<td>End-tidal CO₂ partial pressure</td>
<td>35.60 ± 6.54</td>
<td>33.93 ± 2.68</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3. Respiratory rate (RR) and tidal volume (VT) in smoker and non-smoker patients with panic disorder (PD) and in healthy controls

<table>
<thead>
<tr>
<th>No.</th>
<th>RR</th>
<th>VT</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD patients Smokers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>14.98 ± 4.09</td>
<td>0.62 ± 0.37</td>
</tr>
<tr>
<td>19</td>
<td>16.81 ± 3.71</td>
<td>0.50 ± 0.18</td>
</tr>
<tr>
<td>PD patients Non-smokers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>15.54 ± 2.79</td>
<td>0.45 ± 0.11</td>
</tr>
<tr>
<td>12</td>
<td>13.28 ± 2.97</td>
<td>0.64 ± 0.30</td>
</tr>
<tr>
<td>Healthy controls Smokers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>15.54 ± 2.79</td>
<td>0.45 ± 0.11</td>
</tr>
<tr>
<td>12</td>
<td>13.28 ± 2.97</td>
<td>0.64 ± 0.30</td>
</tr>
<tr>
<td>Healthy controls Non-smokers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>15.54 ± 2.79</td>
<td>0.45 ± 0.11</td>
</tr>
<tr>
<td>12</td>
<td>13.28 ± 2.97</td>
<td>0.64 ± 0.30</td>
</tr>
</tbody>
</table>
normalizing pCO₂ by increasing it (54-56). Moreover, studies reporting a group difference in baseline RR values showed as a limitation the PD patients’ medical status. In our sample, medicated and unmedicated patients did not show differences in respiratory physiology, suggesting that medication did not have an effect on respiration at rest. Our results are in line with those by Siepmann et al. (57) that showed selective serotonin reuptake inhibitors to have no or only minor impact on respiratory pattern.

Results concerning VT and VE are in line with several studies that reported no differences in these values in PD patients compared to HC (19,22,24,58). In a recent review, Nicolai et al. (29) reported that unbalanced samples with regard to gender are likely to induce a bias, because progesterone has been found to be a respiratory stimulant (59,60) able to increase VE values during the luteal phase of the menstrual cycle (61). As a limitation of our study, we did not control for this variable as a possible factor influencing respiration.

No significant differences were found between groups in smoker distribution, in contrast with epidemiological studies (47) that showed smokers to be more prevalent among patients with PD than in healthy subjects.

Interestingly, we found a significant diagnosis-by-smoking interaction effect for the mean values of RR and VT. When assessing the RR and VT mean and standard deviation values of smokers and non-smokers of both groups some observations could be made. In fact, non-smoker patients showed a significantly higher RR compared to non-smoker HC. This evidence could suggest the existence of a different respiratory function between the two groups, in line with the hypothesis of a greater overall variability in baseline respiratory patterns in PD, indicating greater irregularity in their respiratory function. Smoking seems to flatten out this difference, having a dissimilar effect in the two groups. In fact, while in HC the profile of smoker subjects seems to be characterized by higher values of RR and lower values of VT compared with non-smokers, on the contrary in PD patients the profile of smokers seems to be characterized by lower values of RR and higher values of VT compared to non-smokers. Taken together these observations suggest that the effect of nicotine seems to be different in PD patients compared to HC, suggesting the existence of a peculiar equilibrium condition in PD patients. In the literature, daily smoking has been longer associated with an increased risk for later onset of panic attacks or PD (32,34,36). However, the temporal pattern underlying such co-occurrence and the biological mechanisms underlying this association are unknown. According to the false suffocation alarm theory (7), smoking may increase the risk of panic by impairing respiratory system functioning. Our results seem to be consistent with this hypothesis.

In our study the number of subjects who regularly practiced sports was significantly higher in HC than in PD patients, in contrast with previous studies (28). However, this evidence is in line with the fact that physical activity avoidance and agoraphobia could reduce time dedicated to exercise (62) and, accordingly to cognitive theories of PD (63), patients tend to avoid those situations in which bodily symptoms increase and are interpreted as a danger signal. Moreover, anticipatory anxiety and panic attacks mostly occur while patients are physically active compared to a more sedentary status, thus favouring the latest one.

In HC we did not find a significant sport effect on respiratory physiology confirming our previous results (28) indicating that sports activity, at least as assessed in our sample, does not have an effect on respiratory function. This observation could be done only for the HC group, because, in PD patients we found higher mean values of pCO₂ in those who regularly practice sports compared to sedentary patients. It is well known that physical exercise has an effect on respiratory function by stimulating receptor activity of carotid bodies, thus producing ventilatory variation and adaptation during exercise. Moreover, several studies showed higher respiratory variability in PD patients during minimal exercise. Our results suggest that in PD patients physical activity is able to produce a baseline alteration of pCO₂ mean values, indicating a possible dysfunction of those areas involved in the control of ventilatory and chemical variations occurring during physical exercise. However, we did not take into account for levels of physical activity and hours per week that could help to better understand our results. In fact, the anaerobic threshold level is higher in exercised than in sedentary subjects, and this threshold allows the maintenance of a linear correlation between ventilation, CO₂ production and O₂ consumption. It is likely that in PD patients a malfunctioning of those areas involved in the central ventilatory control may determine a difficulty for the respiratory systems to respond adequately to ventilatory variations that are associated with specific levels of physical activity. Respiratory irregularities could be the immediate result of this phenomenon.

**Study limitations**

This study has several limitation. Sample sizes were rather small, and future investigations with larger sam-
amples would be desirable, particularly for the evaluation of smoking and physical activity effects on respiration. We did not assess levels of physical activity and hours per week. Thus, sample differences in these variables may have concealed group differences in respiratory patterns or may have been responsible for the sample differences in pCO2 levels observed. Moreover, all patients were agoraphobic, and this might explain why we found a number of subjects who regularly practiced sports significantly higher in HC compared to PD. Additionally, we could not be able to search for possible differences between agoraphobic and non-agoraphobic patients on respiratory function.

Future studies should also assess the possible effect of menstrual cycle on respiration. Moreover, we did not take into account for age of smoking onset and for the number of cigarettes smoked daily, data that could be relevant for better understanding our results. Further studies with larger samples and controlling for these variables will be necessary.

CONCLUSIONS

The present study provides interesting suggestions to the question of whether PD patients may show respiratory irregularities at rest, and most importantly how smoking and physical activity may affect respiratory physiology. In the PD group, higher mean values of pCO2 were found in those who regularly practice sports compared to sedentary patients and a significant diagnosis-by-smoking interaction effect for the mean values of RR and VT was observed. These findings seem to be in line with the idea of an abnormal regulation of the respiratory system as a key mechanism in PD, and panic and cigarette smoking appear to serve as a causal/predisposing factor in the development of the other. For this reason, the nature of respiratory abnormalities in PD and HC smokers/non-smokers should be compared to better understand the role of smoking in inducing clinical or subclinical abnormalities that may favour panic occurrence (64).

Further studies are warranted to confirm and clarify our results. However, given the complexity of PD in terms of multiple factors that influence not only the onset and maintenance of the disorder but mostly the homeostatic brain functioning, it is firmly necessary that future studies investigate respiratory dynamics in PD assessing the complex interaction between different factors and their possible combined effect on modulating homeostatic brain. This could determine the evaluation on one hand of respiratory and cardiac function in PD, on the other of the combined effects of that variables able to modulate the homeostatic brain functioning. Finally symptom heterogeneity, i.e. symptom subtypes, should be considered, in line to building complex PD neurobiological profiles.

Conflict of interest statement:
Emma Fadda conducted this study as partial fulfilment of her PhD in Molecular Medicine, Program in Experimental Neurology, San Raffaele University, Milan, Italy.

REFERENCES

17. Abelson JL, Nesse RM, Weg JG, Curtis GC. Respiratory psy-
Fadda E et al.


Riv Psychiatr 2013; 48(4): 293-300

300